FindTrial
Sign In

“A phase 2 multi-center study investigating the efficacy, safety and tolerability of pioglitazone in adult participants with non-segmental vitiligo”

Status
Not yet recruiting
Phases
Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2025-523266-24-00
Acronym
2025-523266-24-00
Enrollment
60
Registered
2025-11-26
Start date
Unknown
Completion date
Unknown
Last updated
2025-11-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vitiligo

Brief summary

- Proportion of subjects achieving F-VASI50 (defined as at least 50% improvement in F-VASI from baseline) at Week 16

Interventions

DRUGPioglitazone Mylan 15 mg compresse

Sponsors

I.F.O. Istituti Fisioterapici Ospitalieri
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to 64 Years

Design outcomes

Primary

MeasureTime frame
- Proportion of subjects achieving F-VASI50 (defined as at least 50% improvement in F-VASI from baseline) at Week 16—

Countries

Italy

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026